ASIT biotech announces the achievement of new clinical and corporate development milestones

  • The treatment phase of the confirmatory phase III clinical study with gp-ASIT+™ in grass pollen rhinitis is now completed for all patients, in time before the grass pollen season, with no major safety concerns. DSMB recommends continuing the study without modification.
  • The Company appointed an experienced Chief Financial Officer, Frank Hazevoets, to support its further development.

Brussels, Belgium, May 2, 2019 - 07:00 am CEST - ASIT biotech (ASIT - BE0974289218), a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, today announced the achievement of new clinical and corporate development milestones.

The confirmatory phase III clinical study with gp-ASIT+™ is on track with the last treatment visit of the last patient reached before the start of the pollen season

A total of 651 patients with moderate to severe allergic rhinitis have been treated, above the initial target of 624 patients. This high number of patients has been reached earlier than planned, that reflects the strong interest for the short-course immunotherapy developed by ASIT biotech and provides a solid sample for statistical analysis.

Safety data were followed up by an independent Data Safety Monitoring Board (DSMB) on a weekly basis during this treatment period. The DSMB always recommended to continue the study without modification.

Patients monitoring and data collection in 70 participating European centers is ensured using performant electronic diaries. The whole process during the entire pollen season will be under the tight control of the ASIT biotech clinical team and the dedicated CRO, ICON Plc., with the aim of obtaining primary efficacy results by end-2019 as expected.

Frank Hazevoets appointed as Chief Financial Officer

Previously CFO at Promethera Biosciences, a private biopharmaceutical company targeting liver diseases, Frank Hazevoets has over 25 years’ experience in defining and executing financial strategies for both listed and private companies, raising capital and creating value for shareholders. He held leading financial positions in Investment Banking (Director of Investment Banking at BBL/ING from 1999 to 2001), and the consumer-goods sector (Director Strategy and External Growth at AB InBev from 2001 to 2006). He then entered the life sciences industry as CFO and Company secretary at TiGenix (2006-2012), a Belgian biopharmaceutical company recently acquired by Takeda, where he actively participated in the IPO, supported its funding and growth strategy as well as contributed to the first European marketing authorization obtained for its cell-based drug candidate in cartilage repair.

Frank Hazevoets holds a Master degree in Business Economics and a Master degree in Engineering in Artificial Intelligence & Cognitive Science from the Katholieke Universiteit Leuven (K.U. Leuven).

“I am delighted to join ASIT biotech at a time when the company is executing its confirmatory Phase III study of its lead compound, gp-ASIT+TM. I look forward to working closely with the team in order to continue the excellent work accomplished so far in such a short timeframe on both the financing and scientific fronts. We will capitalize on this sound base and implement a detailed financial roadmap to support the growth of the Company. With the strong involvement of Yves Désiront, we also expect to successfully complete, by the end of the second quarter of 2019, the private placement of convertible notes announced previously,” said Frank Hazevoets, CFO of ASIT biotech.

Michel Baijot, CEO of ASIT biotech, concluded: “Administrating the last gp-ASIT+™ treatment before the start of the pollen season, with no major safety concerns, is a great achievement that considerably de-risks our plan to publish the primary efficacy results by the end of this year. We believe that, given the solid design of this pivotal study, targeting the most allergic patients in regions that are the most exposed to grass pollen, and by using an accurate electronic reporting system, we can collect strong and statistically significant data that will determine the capacity of our innovative immunotherapy to treat such a widespread allergy. Furthermore, we are pleased to welcome Frank Hazevoets to the management team of ASIT biotech at this key stage of our development. His strategic vision combined to his financial expertise will be extremely valuable for our growth. We would also like to thank Yves Désiront for his outstanding commitment to the Company as interim CFO during the important transitional period we have been through, and are glad to count on his support as a board member.”

About ASIT biotech

ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech’s product pipeline contains three novel ASIT+™ product candidates targeting respiratory allergies with the highest prevalence (i.e. grass pollen: gp-ASIT+™ - in ongoing phase III - and house dust mite: hdm-ASIT+™), and food allergies (peanut allergy: pnt-ASIT+™) that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.

ASIT biotech has a headcount of 26 staff members, at its headquarters in Brussels and its facilities in Liège, Belgium.

ASIT biotech
Philippe Ghem
Phone nb.: +32 2 264 03 90

Dusan Oresansky / Pierre Laurent
Media and Investor Relations - France
Phone nb.: +33 1 44 71 94 92

Laure-Eve Monfort
Media Relations - Belgium
Phone nb.: +32 2 290 90 93

Back to news